Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Industry performance is calculated based on the previous closing price of all industry constituents
Largest Companies in This Industry
Name | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
---|---|---|---|---|---|---|---|
166.58 | 213.70 | 44.12% | Buy | ||||
139.82 | 157.92 | 8.17% | Buy | ||||
11.32 | 15.71 | 7.83% | Hold | ||||
56.02 | 56.70 | 5.88% | Hold | ||||
17.11 | 17.75 | 4.91% | Buy | ||||
66.78 | 91.64 | 4.09% | Buy | ||||
75.66 | 104.40 | 3.04% | Buy | ||||
30.76 | 40.50 | 2.43% | Buy | ||||
24.14 | 34.45 | 2.37% | Buy | ||||
13.60 | 16.50 | 2.21% | Buy |
Investing in the Drug Manufacturers - Specialty & Generic Industry
Start Investing in Drug Manufacturers - Specialty & Generic Through These Companies
Top Performing Companies
Name | Last Price | 1Y Target Est. | YTD Return |
---|---|---|---|
25.36 | 26.38 | ||
8.00 | 40.00 | ||
16.89 | 10.75 | ||
7.74 | 17.53 | ||
11.35 | 11.40 |
High Growth Companies
Name | Last Price | Growth Estimate | YTD Return |
---|---|---|---|
38.16 | |||
24.15 | |||
139.82 | |||
42.41 | |||
7.74 |
Drug Manufacturers - Specialty & Generic Research
Discover the Latest Analyst and Technical Research for This Industry
Analyst Report: Catalent, Inc.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
RatingPrice TargetAnalyst Report: Green Thumb Industries Inc.
Green Thumb Industries is headquartered in Chicago, Illinois, and produces and sells medicinal and recreational cannabis through wholesale and retail channels in the United States. It has a presence in 14 states and operates 92 cannabis stores under the brand Rise. GTI is focusing its expansion on limited license states with large populations, and it does not currently export into the global medical market due to U.S. federal prohibition. It offers multiple products under a portfolio of cannabis consumer packaged goods brands, including &Shine, Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles, and RYTHM.
RatingPrice TargetAnalyst Report: Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
RatingPrice TargetAnalyst Report: Dr. Reddy's Laboratories Limited
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
RatingPrice Target